EUVIMEDEUVIMED entdecken
Crossref

Zotarolimus alleviates post-trabeculectomy fibrosis via dual functions of anti-inflammation and regulating AMPK/mTOR axis

Zhiruo Wang, Gong Chen, Haoyu Li, Jingyuan Liu, Yuanyuan Yang, Cong Zhao, Yunping Li, Jingming Shi, Huihui Chen, Guochun Chen

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Zhiruo Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, the Second Xiangya Hospital of Central South University, Changsha, China; Hunan Clinical Research Center of Ophthalmic D…. Hauptthemen laut MEDLINE: Trabeculectomy, Fibrosis, TOR Serine-Threonine Kinases, Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Postoperative scar formation is the primary cause of uncontrolled intraocular pressure following trabeculectomy failure. This study aimed to evaluate the efficacy of zotarolimus as an adjuvant anti-scarring agent in the experimental trabeculectomy. METHODS: We performed differential gene and Gene Ontology enrichment analysis on rabbit follicular transcriptome sequencing data (GSE156781). New Zealand white Rabbits were randomly assigned into three groups: Surgery only, Surgery with mitomycin-C treatment, Surgery with zotarolimus treatment. Rabbits were euthanized 3 days or 28 days post-trabeculectomy. Pathological sections were analyzed using immunohistochemistry, immunofluorescence, and Masson staining. In vitro, primary human tenon's capsule fibroblasts (HTFs) were stimulated by transforming growth factor-β1 (TGF-β1) and treated with either mitomycin-C or zotarolimus. Cell proliferation and migration were evaluated using cell counting kit-8, cell cycle, and scratch assays. Mitochondrial membrane potential was detected with the JC-1 probe, and reactive oxygen species were detected using the DCFH-DA probe. RNA and protein expressions were quantified using RT-qPCR and immunofluorescence. RESULTS: Transcriptome sequencing analysis revealed the involvement of complex immune factors and metabolic disorders in trabeculectomy outcomes. Zotarolimus effectively inhibited fibrosis, reduced proinflammatory factor release and immune cell infiltration, and improved the surgical outcomes of trabeculectomy. In TGF-β1-induced HTFs, zotarolimus reduced fibrosis, proliferation, and migration without cytotoxicity via the dual regulation of the TGF-β1/Smad2/3 and AMPK/AKT/mTOR pathways. CONCLUSION: Our study demonstrates that zotarolimus mitigates fibrosis by reducing immune infiltration and correcting metabolic imbalances, offering a potential treatment for improving trabeculectomy surgical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrabeculectomyFibrosisTOR Serine-Threonine KinasesFibroblastsSirolimusSignal TransductionAnimalsRabbitsHumansAMP-Activated Protein KinasesCells, CulturedTenon CapsuleAnti-Inflammatory AgentsCell ProliferationMaleGlaucomaCell MovementPostoperative Complications

Stichwörter der Autor:innen

Adenosine monophosphate-activated protein kinase (AMPK)Anti-fibrosisGlaucomaMammalian target of rapamycin (mTOR)TrabeculectomyZotarolimus

Substanzen

TOR Serine-Threonine KinasesSirolimusAMP-Activated Protein KinasesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, the Second Xiangya Hospital of Central South University, Changsha, China; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China.
  • Department of Ophthalmology, the Second Xiangya Hospital of Central South University, Changsha, China; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, China; Clinical Immunology Research Center of Centra…
  • Clinical Immunology Research Center of Central South University, Changsha, China; Department of Nephrology, the Second Xiangya Hospital of Central South University, Changsha, China.

Förderung

  • Fundamental Research Funds for Central Universities of the Central South University
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Z., Chen, G., Li, H., Liu, J., Yang, Y., Zhao, C., Li, Y., Shi, J., Chen, H., & Chen, G. (2024). Zotarolimus alleviates post-trabeculectomy fibrosis via dual functions of anti-inflammation and regulating AMPK/mTOR axis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113176

Vancouver

Wang Z, Chen G, Li H, Liu J, Yang Y, Zhao C, et al. Zotarolimus alleviates post-trabeculectomy fibrosis via dual functions of anti-inflammation and regulating AMPK/mTOR axis. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113176

BibTeX
@article{Wang2024,
  author = {Wang, Zhiruo and Chen, Gong and Li, Haoyu and Liu, Jingyuan and Yang, Yuanyuan and Zhao, Cong and Li, Yunping and Shi, Jingming and Chen, Huihui and Chen, Guochun},
  title = {Zotarolimus alleviates post-trabeculectomy fibrosis via dual functions of anti-inflammation and regulating AMPK/mTOR axis},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113176}
}
Kostenlos starten →